Company Overview: Adamas Pharmaceuticals (ADMS) is a late stage Northern California based pharmaceutical company that is focusing on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company has a market capitalization of approximately $350 million and a stock price of just over $17.00 a share. The shares have a 52-week of slightly north of $30 a share. Adamas came public in the first half of 2014.
Insider Buying: A director and beneficial owner, William Ericson, has picked up over $3,000,000 in new shares in myriad transactions since September 6th. Another beneficial owner has added about $3.1 million in new shares in five transactions since September 2nd. This is the first insider buying in the stock since April of 2014.